OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Andreadis on Treatment Approaches in Relapsed MCL

January 4th 2020

Charalambos (Babis) Andreadis, MD, MSCE, discusses the need to identify an optimal standard of care in patients with relapsed/refractory mantle cell lymphoma.

Dr. Lazarides on Challenges in Moving the Field of Osteosarcoma Forward

January 4th 2020

Alexander Leandros Lazarides, MD, discusses some of the current challenges in moving the field forward in osteosarcoma.

Dr. Borghaei on Immune-Related Adverse Events in Lung Cancer

January 3rd 2020

Hossein Borghaei, DO, MS, discusses immune-related adverse events in patients with lung cancer who received immunotherapy/chemotherapy combinations.

Dr. Vaishampayan on the Role of Cytoreductive Nephrectomy in mRCC

January 3rd 2020

Ulka Vaishampayan, MD, professor of oncology at Wayne State University, and the chief of the Solid Tumor Program at Barbara Ann Karmanos Cancer Institute, discusses the current role of cytoreductive nephrectomy in metastatic renal cell carcinoma.

Dr. Heath on the Toxicity Profiles of Oral Antiandrogens in Nonmetastatic CRPC

January 3rd 2020

Elisabeth I. Heath, MD, FACP, discusses the safety profiles of apalutamide, enzalutamide, and darolutamide in nonmetastatic castration-resistant prostate cancer.

Dr. Moore on Treatment for Patients With Ovarian Cancer Who Develop Resistance to PARP Inhibitors

January 3rd 2020

Kathleen Moore, MD, director, Oklahoma TSET Phase I Program, and associate professor, Section of Gynecologic Oncology, Stephenson Cancer Center, discusses treatment for patients with ovarian cancer who progress on a PARP inhibitor.

Dr. Woyach on Frontline Treatment Options in CLL

January 3rd 2020

Jennifer Woyach, MD, discusses frontline treatment options for patients with chronic lymphocytic leukemia.

Dr. Vaishampayan on Immunotherapy Trials in Kidney Cancer

January 3rd 2020

Ulka Vaishampayan, MD, discusses trials that examine frontline immunotherapy for metastatic kidney cancer.

Dr. Martin on Subcutaneous Administration of Daratumumab in Multiple Myeloma

January 3rd 2020

Thomas G. Martin, MD, discusses the impact of subcutaneous administration of daratumumab on patients with early relapse multiple myeloma.

Dr. Wong on Investigational CAR T-Cell Products in Multiple Myeloma

January 3rd 2020

Sandy Wong, MD, discusses investigational CAR T-cell products in relapsed/refractory multiple myeloma.

Dr. Sznol on Managing Patients Beyond Initial Treatment in Melanoma

January 3rd 2020

Mario Sznol, MD, discusses the management of patients with melanoma who progress on immune checkpoint inhibitors.

Experts Provide Insight on the Biggest Advances in Oncology in 2019

January 1st 2020

OncLive interviewed experts at the State of the Science Summits™ in December 2019 on what the biggest advances in oncology were in 2019.

Dr. Emens on the Future of Immunotherapy in Ovarian Cancer

December 23rd 2019

Leisha A. Emens, MD, PhD, discusses a potential future with immunotherapy in ovarian cancer.

Dr. Rizk on the Role of Surgery in Nonmetastatic Lung Cancer

December 23rd 2019

Nabil P. Rizk, MD, MS, MPH, discusses the role of anatomic surgical resection in nonmetastatic lung cancer.

Dr. Olin on the Utility of Venetoclax in AML

December 23rd 2019

Rebecca L. Olin, MD, MSCE, associate professor, Department of Medicine (Hematology/Oncology), University of California San Francisco, discusses the utility of venetoclax in acute myeloid leukemia.

Dr. Levy on Treatments for Oncogenic-Driven NSCLC

December 21st 2019

Benjamin P. Levy, MD, discusses treatment options for patients with oncogenic-driven non–small cell lung cancer.

Dr. Crafton on the Impact of PARP Inhibitors in Recurrent Ovarian Cancer

December 21st 2019

Sarah Crafton, MD, discusses the impact of PARP inhibitors on patients with recurrent ovarian cancer.

Dr. Fakhri on Ibrutinib-Containing Regimens in CLL

December 21st 2019

Bita Fakhri, MD, MPH, discusses the trials that led to ibrutinib-containing regimens becoming the standard of care for chronic lymphocytic leukemia over traditional chemotherapy options.

Dr. Traina on the FDA Approval of Trastuzumab Deruxtecan for HER2+ Breast Cancer

December 21st 2019

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201) for patients with HER2-positive, locally advanced, or metastatic breast cancer who have been treated with trastuzumab (Herceptin) and pertuzumab (Perjeta) and have disease progression after ado-trastuzumab emtansine (T-DM1; Kadcyla).

Dr. Gralow on the Global Impact of Biosimilars

December 20th 2019

Julie R. Gralow, MD, clinical director, Breast Medical Oncology, Seattle Cancer Care Alliance, professor, medical oncology, University of Washington School of Medicine, discusses the global impact of biosimilars in HER2-positive breast cancer.